Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23026169 | 0.83 | HPGD (0.60) | HPGDPOLBALDH1A1KDM4ES1PR2 | |
| SCHEMBL20514052 | 0.81 | PKM (0.44) | HPGDPOLBALDH1A1RAB9AGAA | |
| SCHEMBL20514287 | 0.81 | HPGD (0.49) | HPGDPOLBALDH1A1KDM4ES1PR2 | |
| SCHEMBL23026172 | 0.78 | HPGD (0.44) | HPGDPOLBALDH1A1KDM4ES1PR2 | |
| SCHEMBL8790854 | 0.73 | POLB (0.71) | HPGDPOLBTSHRKLK7 | |
| SCHEMBL20514138 | 0.73 | DRD2 (0.45) | ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL6666790 | 0.71 | GAA (0.72) | HPGDPOLBTSHRALDH1A1KDM4E | |
| SCHEMBL20514063 | 0.70 | POLB (0.64) | HPGDPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL23026125 | 0.69 | HPGD (0.41) | HPGDPOLBALDH1A1KDM4ES1PR2 | |
| SCHEMBL20515251 | 0.69 | HPGD (0.50) | HPGDPOLBTSHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-08-27 | — | — | US | disclosed |
| EP-3380970-B1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-10-26 | — | — | US | disclosed |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-21 | — | — | US | disclosed |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180282289-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
| EP-3380970-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | HPGD 4292/4885POLB 4867/4885TSHR 481/4885 |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | HPGD 4292/4885POLB 4867/4885TSHR 481/4885 |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | HPGD 4302/4885POLB 4857/4885TSHR 579/4885 |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | HPGD 4319/4885POLB 4846/4885TSHR 573/4885 |
| US-20180282289-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | HPGD 4280/4885POLB 4851/4885TSHR 556/4885 |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | HPGD 4244/4885POLB 4868/4885TSHR 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.